antibodies, antiphospholipid

Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events
Dionysis Nikolopoulos, Catherine Loukogiannaki, George Sentis, Panagiotis Garantziotis, Theodora Manolakou, Noemin Kapsala, Myrto Nikoloudaki, Antigone Pieta, Sofia Flouda, Ioannis Parodis, George Bertsias, Antonis Fanouriakis, Anastasia Filia, Dimitrios T Boumpas

Annals of the Rheumatic Diseases Apr 2024, ard-2024-225664; DOI: 10.1136/ard-2024-225664
Single-cell transcriptome analyses reveal disturbed decidual homoeostasis in obstetric antiphospholipid syndrome
Chenyang Lu, Rui Gao, Pingying Qing, Xun Zeng, Xin Liao, Meng Cheng, Lang Qin, Yi Liu

Annals of the Rheumatic Diseases May 2024, 83 (5) 624-637; DOI: 10.1136/ard-2023-224930
Prevalence of clinically meaningful antiphospholipid antibodies in patients with systemic lupus erythematosus varies by race and ethnicity
Cécile M Yelnik, Xianhong Xie, Marta M Guerra, Nathalie Costedoat-Chalumeau, Arezou Khosroshahi, Diane L Kamen, Noa Schwartz, Patricia Katz, Margaret Minett, R Toby Amoss, April Fu, Gaëlle Guettrot-Imbert, Estibaliz Lazaro, Véronique Le Guern, Jim Oates, Maria Dall'Era, Jinoos Yazdany, Anna Molto, Mimi Y Kim, Jane E Salmon

Annals of the Rheumatic Diseases Mar 2024, 83 (3) 404-406; DOI: 10.1136/ard-2023-224952
Correspondence on ‘2023 ACR/EULAR antiphospholipid syndrome classification criteria’
Francesc A Miro-Mur, Jaume Alijotas-Reig, Ariadna Anunciacion-Llunell, Joana Marques-Soares, Enrique Esteve-Valverde, Jose Pardos-Gea

Annals of the Rheumatic Diseases Mar 2024, 83 (3) e2; DOI: 10.1136/ard-2023-225042
Response to: Correspondence on ‘2023 ACR/EULAR antiphospholipid syndrome classification criteria’ by Miro-Mur et al
Doruk Erkan, Medha Barbhaiya, Stephane Zuily, Maria Laura Bertolaccini, Rohan Willis, Katrien Devreese

Annals of the Rheumatic Diseases Mar 2024, 83 (3) e3; DOI: 10.1136/ard-2023-225054
Correspondence on ‘2023 ACR/EULAR antiphospholipid syndrome classification criteria’
Zihan Tang, Hui Shi, Hong-Lei Liu, Xiaobing Cheng, Junna Ye, Yutong Su, Qiongyi Hu, Jianfen Meng, Haoyu Pan, Chengde Yang, Jialin Teng, Tingting Liu

Annals of the Rheumatic Diseases Mar 2024, 83 (3) e4; DOI: 10.1136/ard-2023-225013
Response to: Correspondence on ‘2023 ACR/EULAR antiphospholipid syndrome classification criteria’ by Tang et al
Medha Barbhaiya, Stephane Zuily, Alison M Hendry, Florian Manneville, Francis Guillemin, Karen H Costenbader, Doruk Erkan

Annals of the Rheumatic Diseases Mar 2024, 83 (3) e5; DOI: 10.1136/ard-2023-225026
Response to: Correspondence on ‘ACR/EULAR antiphospholipid syndrome classification criteria’ by Damoiseaux and van Beers
Medha Barbhaiya, Stephane Zuily, Maria Laura Bertolaccini, Rohan Willis, Katrien Devreese, Doruk Erkan

Annals of the Rheumatic Diseases Mar 2024, 83 (3) e7; DOI: 10.1136/ard-2023-225074
Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial—comment on: ‘Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus’ by Chatzidionysiou et al
Alessandra Bettiol, Francesca Pregnolato, Savino Sciascia, Giacomo Emmi, Domenico Prisco, Pier Luigi Meroni

Annals of the Rheumatic Diseases Aug 2022, 81 (8) e140; DOI: 10.1136/annrheumdis-2020-218377
Response to: ‘Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial–comment on: ‘Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus’ by Chatzidionysiou et al’ by Bettiol et al
Katerina Chatzidionysiou, Evangelia Samoli, Petros P Sfikakis, Maria G Tektonidou

Annals of the Rheumatic Diseases Aug 2022, 81 (8) e141; DOI: 10.1136/annrheumdis-2020-218444

Main menu

antibodies, antiphospholipid

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

antibodies, antiphospholipid

Pages